2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1878

Proteomics Analysis Of Cartilage Secretome: A Powerful Tool For The Discovery Of OA Biomarkers
Abstract Number: 2720

Providing Comprehensive, Comparative Post-TJR Outcome Feedback To Surgeons For Quality Monitoring and Value Decisions
Abstract Number: 1035

Psoriatic Arthritis and Mortality – a Nationwide Study
Abstract Number: 351

Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review
Abstract Number: 1011

Psychiatric and Cardiovascular Comorbidities As Causes Of Work Disability Among Individuals With Rheumatoid Arthritis
Abstract Number: 2208

Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Abstract Number: 1033

Psychological status correlates of disease activity and sleep quality in patients with Ankylosing Spondylitis: A case-control study
Abstract Number: 828

Psychosocial Determinants Of Total Knee Arthroplasty Outcomes 2 Years After Surgery
Abstract Number: 1299

PTEN Controls Osteoclastogenesis and Inflammatory Bone Destruction In a TNF-Driven Model Of Arthritis
Abstract Number: 738

Pulmonary Fibrosis In ANCA-Associated Vasculitis
Abstract Number: 2078

Pulmonary Hypertension In Anti-Jo1 Syndrome
Abstract Number: 2588

Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Abstract Number: 2578

Pulmonary Hypertension In Systemic Sclerosis: Clinical Classification and Pulmonary Hypertension Subtypes
Abstract Number: 693

Pulmonary Involvement In Mixed Connective Tissue Disease: Slow Progression After 10 Years Of Follow-Up
Abstract Number: 560

Purified IgG From Patients With Systemic Lupus Erythematosus Enhances Apoptosis In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].